Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Colm Keane

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphomaKimberley Jones, Frank Vari, Colm Keane, et al.
Hematological Oncology|June 16, 2006
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationColm Keane, Simon Gibbs, John F Seymour, et al.
Haematologica|March 21, 2024
Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillanceJoel Wight, Piers Blombery, Jennifer Lickiss, et al.
Journal of Virological Methods|May 22, 2012
Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samplesJamie P Nourse, Pauline Crooks, Colm Keane, et al.
British Journal of Haematology|May 16, 2026
Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practiceElizabeth Goodall, Jodie Palmer, Arina Martynchyk, et al.
Neuro-Oncology Advances|June 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRIJack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee, et al.
European Journal of Haematology|June 19, 2019
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphomaColm Keane, Joshua Tobin, Jay Gunawardana, et al.
Acta Haematologica|October 23, 2022
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic LeukemiaMelinda Burgess, Colm Keane, Josh Wd Tobin, et al.
Clinical & Translational Immunology|November 8, 2021
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapyMohamed Shanavas, Soi-Cheng Law, Mark Hertzberg, et al.
Blood|December 20, 2019
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2Alexandre S Cristino, Jamie Nourse, Rachael A West, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2012
Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphomaKimberley Jones, Frank Vari, Colm Keane, et al.
Hematological Oncology|June 16, 2006
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilizationColm Keane, Simon Gibbs, John F Seymour, et al.
Haematologica|March 21, 2024
Systemic diffuse large B-cell lymphoma involving the central nervous system has high rates of defective antigen presentation and immune surveillanceJoel Wight, Piers Blombery, Jennifer Lickiss, et al.
Journal of Virological Methods|May 22, 2012
Expression profiling of Epstein-Barr virus-encoded microRNAs from paraffin-embedded formalin-fixed primary Epstein-Barr virus-positive B-cell lymphoma samplesJamie P Nourse, Pauline Crooks, Colm Keane, et al.
British Journal of Haematology|May 16, 2026
Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practiceElizabeth Goodall, Jodie Palmer, Arina Martynchyk, et al.
Neuro-Oncology Advances|June 27, 2025
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRIJack O'Shaughnessy, Arina Martynchyk, Sze Ting Lee, et al.
European Journal of Haematology|June 19, 2019
The tumour microenvironment is immuno-tolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphomaColm Keane, Joshua Tobin, Jay Gunawardana, et al.
Acta Haematologica|October 23, 2022
Resolution of Melanoma to Programmed Death-1 Blockade but Simultaneous Rapid Progression of Concomitant Chronic Lymphocytic LeukemiaMelinda Burgess, Colm Keane, Josh Wd Tobin, et al.
Clinical & Translational Immunology|November 8, 2021
Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapyMohamed Shanavas, Soi-Cheng Law, Mark Hertzberg, et al.
Blood|December 20, 2019
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2Alexandre S Cristino, Jamie Nourse, Rachael A West, et al.
Pageof 7